HULIO (1ML)
ADALIMUMAB
What it does
Adalimumab is a medicine used to help manage certain autoimmune conditions by reducing inflammation in the body.
Commonly used for: rheumatoid arthritis, psoriasis, inflammatory bowel disease, ankylosing spondylitis …
Read more in plain English ↓Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.
Ask about this medicine
Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.
Medicine sourcing is available in Kenya only. We don't sell or dispense medicines - licensed pharmacies do.
Sourcing - Kenya onlyRegistration & product details
Source: Medicines Control Authority of Zimbabwe · fetched 2026-04-18 08:22:07 · updated 2026-09-16 04:30:07
Drug Interactions
1Pharmacodynamic Warnings
Adalimumab appears in TABLE 15: Drugs that cause myelosuppression
Severe (1)
Adalimumab - increases risk of immunosuppression
Filgotinib is predicted to increase the risk of immunosuppression when given with monoclonal antibodies (adalimumab, certolizumab pegol, golimumab, infliximab, rituximab, sarilumab, secukinumab, tocil
Data from BNF 85 (British National Formulary). This is not a substitute for professional medical advice. Matched via: exact
About this medicine
Adalimumab is a medicine used to help manage certain autoimmune conditions by reducing inflammation in the body.
What it treats
- rheumatoid arthritis
- psoriasis
- inflammatory bowel disease
- ankylosing spondylitis
- juvenile idiopathic arthritis
How it works
It works by blocking a substance in the body that leads to inflammation, helping to reduce symptoms and improve quality of life.
Who it's for
This medicine is for adults and children with specific autoimmune diseases that cause inflammation.
Cautions
- • Be careful if you're taking other medicines that affect blood cell production.
AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.
Clinical monograph: Adalimumab
BNF-referencedAdalimumab is a monoclonal antibody that inhibits tumor necrosis factor-alpha (TNF-alpha), a pro-inflammatory cytokine involved in inflammatory processes. It is used to treat various autoimmune diseases.
Indications
- Plaque psoriasis
- Polyarticular juvenile idiopathic arthritis
- Enthesitis-related arthritis
- Crohn's disease
Dosage
Children: Child 4–17 years (body-weight 15–29 kg): Initially 20 mg once weekly for 2 doses, then 20 mg every 2 weeks. Child 4–17 years (body-weight 30 kg and above): Initially 40 mg once weekly for 2 doses, then 40 mg every 2 weeks. Child 2–17 years (body-weight 10–29 kg): 20 mg every 2 weeks. Child 2–17 years (body-weight 30 kg and above): 40 mg every 2 weeks. Child 6–17 years (body-weight 15–29 kg): 20 mg every 2 weeks. Child 6–17 years (body-weight 30 kg and above): 40 mg every 2 weeks.
Adults: Refer to the BNF for specific adult dosing recommendations.
Mechanism of action
Adalimumab binds specifically to TNF-alpha, preventing it from interacting with its receptors, which reduces inflammation and alters the immune response.
Pharmacodynamics
By inhibiting TNF-alpha, adalimumab decreases inflammatory processes and the symptoms associated with autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn's disease.
Pharmacokinetics
Adalimumab is administered by subcutaneous injection. It has a long half-life, allowing for less frequent dosing. The pharmacokinetics can vary based on patient factors such as weight and disease state.
Adverse effects
- Asthenia
- Cough
- Diarrhoea
- Dizziness
- Gastrointestinal discomfort
- Headaches
- Hypertension
- Increased risk of infection
- Nausea
- Oral ulceration
- Skin reactions
- Vomiting
- Alopecia
- Anxiety
- Arrhythmias
- Arthralgia
- Bruising tendency
- Conjunctivitis
- Depression
- Dry eye
- Dyspnoea
- Gastritis
- Hyperhidrosis
- Hypotension
- Influenza-like illness
- Leucopenia
- Menstrual cycle irregularities
- Pain in extremity
- Palpitations
- Paresthesia
- Respiratory disorders
- Sepsis
- Sleep disorders
- Throat tightness
- Thrombocytopenia
- Vasculitis
- Vertigo
- Visual acuity decreased
- Weight increased
Interactions
- Filgotinib: Severe (increases risk of immunosuppression)
Precautions
- Children should be brought up to date with current immunisation schedule before initiating therapy.
- Do not initiate until active infections are controlled.
- Discontinue treatment if neurological symptoms present.
Pregnancy
Manufacturer advises avoid unless essential.
Breast-feeding
Present in milk in animal studies-manufacturer advises avoid breast-feeding during treatment and for 14 weeks after last dose.
Storage
Store at 2 to 8 degrees Celsius. Do not freeze.
Formulations
- Subcutaneous injection
AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.
This drug in other countries
The same active ingredient registered across other registries we cover - including different brands.